Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Search News Archive

Perspective
What's the King review think it's doing?
Is the King review sending industry a message that disruptive reform of the PBS is anything but over despite MA's agreement with government?
Approvals Action
First threat to $63m pain drug
Sandoz's new generic competitor could make a serious hole in the drug that represents close to 40 per cent of Mundipharma's total PBS earnings.
Pipeline Monitor
FDA issues flood of approvals
The US regulatory body issued a number of approvals this week including a new combination use for Janssen's oncology med Darzalex and two ADHD meds.